Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-08
2005-02-08
Kunz, Gary (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06852724
ABSTRACT:
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.
REFERENCES:
patent: 4567264 (1986-01-01), Kluge et al.
patent: 5209933 (1993-05-01), MacFarlane et al.
patent: 5472707 (1995-12-01), Samuels et al.
patent: 5506229 (1996-04-01), Dow et al.
patent: 5670171 (1997-09-01), Santus et al.
patent: 5906988 (1999-05-01), Dow et al.
patent: 6303607 (2001-10-01), Wolff et al.
patent: 6479496 (2002-11-01), Wolff
patent: 6525057 (2003-02-01), Wolff et al.
patent: 6620814 (2003-09-01), Wolff et al.
patent: WO 9426266 (1994-11-01), None
Allely MC, Alps BJ. Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br J Pharmacol 99:5-6, 1990.
Jain D, Dasgupta P, Hughes LO, Lahiri A, Raftery EB. Ranolazine (RS-43285): A preliminary study of a new anti-anginal agent with selective effect of ischaemic myocardium. Eur J Clin Pharmacol 38:111-114, 1990.
Lodge JPA, Lam FT, Perry SL, Giles GR. Ranolazine—a new drug with beneficial effects on renal preservation. Transplantation 50:755-759, 1990.
Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, Pouleur H. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with β-blocker or diltiazem. J Cardiovasc Pharmacol 20:131-138, 1992.
Allely MC, Brown CM, Kenny BA, Kilpatrick AT, Martin A, Spedding M. Modulation of a1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: protection by ranolazine. J Cardiovasc Pharmacol 21:869-873, 1993.
Clarke B, Spedding M, Patmore L, McCormack JG. Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br J Pharmacol 109:748-750, 1993.
Black SC, Gralinski MR, McCormack JG, Driscoll EM, Lucchesi BR. Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion. J Cardiovasc Pharmacol 24:921-928, 1994.
Gralinski MR, Black SC, Kilgor KS, Chou AY, McCormack JG, Lucchesi BR. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovascular Research 28:1231-1237, 1994.
Hayashida W, Eyll CV, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovascular Drugs and Therapy 8:741-747, 1994.
Thadani U, Exekowitz M, Fenney L, Chiang YK. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Circulation 90:726-734, 1994.
Herron WJ, Eadie J, Penman AD. Estimaiton of ranolazine and eleven Phase I metabolites in human plasma by liquid chromatography—atmospheric pressure chemical ionisation mass spectrometry with selected -ion monitoring. Journal of Chromatography A 712:55-60, 1995.
Penman AD, Eadie J, Herron WJ, Reilly MA, Rush WR. The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry. Rapid Communications in Mass Spectrometry 9:1418-1430, 1995.
Wyatt KM, Skene C, Veitch K, Hue L, McCormack JG. The anti-anginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondra. Biochemical Pharmacol 50:1599-1606, 1995.
Allen TJ, Chapman RA. Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes. Br J Pharmacol 118:249-254, 1996.
Clarke B, Wyatt KM, McCormack JG, Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol 28:341-350, 1996.
McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 93:135-142, 1996.
McCormack JG, Baracos VE, Barr R, Lopaschuk GD. Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle. Am Physiol Society, 905-910, 1996.
Wang JX, et al., “Antianginal effects of ranolazine in various experimental models of angina.” Arzeinmittelforschung Mar. 1999; 49(3): 193-9.
Matsumura H., et al. “Protective effects of ranolazine, a novel anti-ischemic drug on the hydrogen peroxide-induced derangements in isolated, perfused rate heart: comparison with dichloroacetate.” Jpn J Pharmacol. May 1998; 77(1)31-9.
McCormack JG, et al., “Ranolazine; a novel metabolic modulator for the treatment of angina.” Gen Pharmacol. May 1998; 30(5): 639-45.
Bagger JP, et al., “Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease.” Cardiovase Drugs Ther. Jul. 1997;11(3): 479-84.
Aaker A, et al., “Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarcation.” J Cardiovasc Pharmacol. Sep. 1996; 28(3):353-62.
Allely MC, Alps BJ, Kilpatrick AT. The effects of the novel anti-anginal agent RS-43285 on [lactic acid], [K+] and pH in a canine model of transient myocardial ischaemia. Biochemical Society Transactions 622ndMeeting, Leicester 15:1057-1058, 1987.
Alley MC, Alps BJ. The effects of the novel anti-anginal agent ranolazine (I.D.) in a canine model of transient myocardial ischaemia. Br J Pharmacol 93(Suppl):246P, 1988.
Brown CM, Clarke B. Dye A, Fraser S, Kenny BA, Kilpatrick AT, Patmore L, Spedding M, Whiting RL. Pharmacological profile of ranolazine, a metabolic modulator active in ischaemia. Br J Pharmacol 93(Suppl):248P, 1988.
Ferrandon P, Pascall JC, Armstrong JM. Protective effects of the novel anti-ischaemic agent ranolazine (RS-43285) in perfused rat hearts. Br J Pharmacol 93(Suppl):247P, 1988.
Pouleur H, Hue L, Harlo BJ, Rousseau MF. Metabolic pathways modulation: a new approach to treat myocardial ischemia? Circulation 80, (Supp II):52, 1989.
Ferrandon P, Chaylat C, Armstron JM. Free radical scavengers fail to increase the protective effects of ranolazine in isolated working rat hearts after ischemia and reperfusion. Eur J Pharmacol 183:328-329, 1990.
Ferrandon, P et al. Ranolazine but not allopurinol or dipyridamole reduces the ventricular acidosis and lactate produced by low perfusion flow in isolated rat hearts. Therapie 45:10, 1990.
Cocco G, Rousseau MF, Bouvy T, Cheron P, William C, Detry JM, Pouleur H. Effects of a novel metabolic modulator, ranolazine, on exercise tolerance and left ventricular filling dynamics in patients with angina petoris. Eur Heart J 13(Supp):97, 1992.
Rousseau MF, Cocco G, Bouvy T, Cheron P, William GJ, Detry JMR, Pouleur H. Effects of a novel metabolic modulator, ranolazine, on exercise tolerance and left ventricular filling dynamics in patients with angina petoris. Circulation 86(Supp I):2843, 1992.
Rousseau MF, Van Eyll C, Van Mechelen H, Harlow BJ, Pouleur H. Novel metabolic ranolazine selectively improves diastolic function in heart failure. Circulation 86(Suppl):375, 1992.
Collins-Nakai RL, Barr R, Humen D, Lopaschuk GD. Ranolazine stimulates glucose oxidation in isolated working rat hearts. Can J Cardiol 9(Supp E):104E, 1993.
Rousseau MR, Visser FG, Bax JJ, Dubrey S, Cocco G, Pouleur H, Harris SA, Wolff AA. Ranolazine: anti-anginal therapy with a novel mechanism: placebo controlled comparison versus atenolol. Eur Heart J 15 (Suppl I):95, 1994.
Rousseau MR, Visser FG, Bax JJ, Noble MIM, Dubrey S, Cocco G, Pasteuning WH, Williams G, Dodds P, Pouleur H. Is modulation of myocardial metabolism as effective as β-blockade in exercise-induced angina? J Am Coll Cardiol 23 (Supp I):268A, 1994.
Smith WB, Chrysant S, Garland WT, Parker TS, Walpol
CV Therapeutics Inc.
CV Therapeutics, Inc.
George Konata M.
Kunz Gary
LandOfFree
Sustained release ranolazine formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained release ranolazine formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release ranolazine formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3506681